Success Story: Only 25 days for a Scientist II from India to Gain EB1B Approval under Premium Processing

Posted by wegreened on February 6, 2026 in EB1 Green Card, Epigenetics

Client’s Testimonial:

“Chen group of immigration attorneys is an excellent group of lawyers to work with for EB1 cases. They crafted an exceptional petition letter to accompany all the evidence I had gathered for my application. They helped me select recommenders and drafted letters of support that needed minimal editing from the recommenders. Their attention to detail is great, often checking and double-checking with me to confirm everything is consistent throughout the application. Turn-around times for messages/review on their portal can be slow at times, so I highly recommend asking for changes/review in the least number of iterations so there is less back and forth and waiting for them to respond. Overall, I highly recommend working with them for EB1-based applications.”

On January 13^th, 2026, we received another EB-1B (Outstanding Professors and Researchers) approval for a Scientist II in the Field of Cancer Epigenetics (Approval Notice).

General Field: Cancer Epigenetics

Position at the Time of Case Filing: Scientist II

Country of Origin: India

Approval Notice Date: January 13^th, 2026

Processing Time: 25 days (Premium Processing Requested)

Case Summary:

"Ensuring the continuation of [Client]’s work is thus deeply important to both cancer epigenetics research and to international matters in expanding safe and precise cancer therapies."

This powerful endorsement was one of three recommendation letters for an exceptional scientist from India, whose groundbreaking work in cancer epigenetics is reshaping therapeutic approaches for some of the most aggressive forms of cancer. With a Ph.D. in biochemistry, structural and stem cell biology, this researcher represents the caliber of talent driving American biomedical innovation forward.

Drawing on our proven success with over 32,000 cases, our expert team crafted a compelling EB-1B petition that achieved remarkable approval in just 25 days under premium processing without a Request for Evidence.

Revolutionary Impact on Cancer Treatment

The client's research tackles one of medicine's greatest challenges: developing minimally toxic, targeted treatments for aggressive, treatment-resistant cancers. This work focuses on understanding the epigenetic mechanisms that drive hematological malignancies, neuronal development pathways, and melanoma progression, opening unprecedented therapeutic avenues that could transform patient outcomes while reducing long-term treatment costs.

By investigating critical epigenetic regulators and their roles in cancer emergence and progression, this research addresses vital national health priorities and positions the United States as the global leader in precision oncology and biotech innovation.

Elite Recognition and Extraordinary Impact

Publishing Excellence: 10 peer-reviewed journal articles (4 first-authored, 1 co-first-authored)
Global Influence: 303 citations earned, placing this researcher among the top 1% of most highly cited authors
Expert Authority: 18 peer reviews conducted for prestigious journals, plus editorial board membership
Major Funding: Research supported by the National Institutes of Health (NIH), American Society of Hematology (ASH), American Cancer Society (ACS), Blood Cancer United, National Cancer Institute (NCI), and National Institute of Environmental Health Sciences (NIEHS)

Strategic National Importance

This research directly addresses critical U.S. healthcare challenges and economic priorities. By advancing safer, precision-based cancer treatments, the work has the potential to reduce the billions spent annually on cancer care while dramatically improving survival rates for patients with aggressive malignancies. The innovations foster therapeutic strategies that enhance global health equity and position American pharmaceutical development at the forefront of precision medicine, ensuring continued leadership in the competitive biotech sector.

Conclusion

This exceptionally rapid approval reflects both the undeniable strength of the petition and the extraordinary caliber of the researcher's achievements. We are honored to have supported this journey and look forward to the life-saving contributions ahead.

--------------------------------------------

North America Immigration Law Group (Chen Immigration Law Associates) is a U.S. immigration law firm dedicated to representing corporations, research institutions, and individuals from all 50 U.S. states regarding I-140 immigration petitions. We specialize in employment-based immigration petition and have a proven record of high success rate for the categories of: EB2-NIW (National Interest Waiver), EB1-A (Alien of Extraordinary Ability), EB1-B (Outstanding Researcher/Professor) and O-1 (Alien of Extraordinary Ability).

Our Sixty-four Thousand I-140 Approvals Provide Unprecedented Insight into the USCIS Adjudication Trend

With nearly 64,000 EB-1A, EB-1B, EB-2 NIW and O-1 cases approved, we have first hand information on the manner in which the USCIS adjudicate I-140 cases. As the USCIS has constantly changed its adjudication standards for the EB-1A, EB-1B and EB-2 NIW categories, our firm's huge database of successful cases gives you unprecedented insight to USCIS adjudication trends. We carefully analyze the data for all of our cases and apply the results of our analyses toward giving our clients up-to-date advice and adapting our strategies such that we remain on par with the ever-shifting landscape of immigration law in the U.S. With us, you will always have access to important updates, strategies, and information so that you can make the most informed decisions about your case.

We Have Helped Tens of Thousands of Clients with Credentials and Backgrounds Similar to Yours

With our exceedingly large number of successful petitions, no matter what credentials you have, no matter your background and field of expertise, no matter your visa status or nationality, chances are we have helped hundreds or even thousands of clients just like you. Our clients are usually impressed with how well we understand their research and work. Our insight and understanding stems from the fact that we have handled many cases with elements similar to yours already, and this helps us devise the best strategies for each individual petition.

Vast Majority of Clients Came to Us Because of Referrals

For years, our firm has attracted new clients based solely on word of mouth, recommendations, and the positive collaboration experiences shared with them by their friends and family. We take pride in our reputation and work hard to ensure that we provide a green card application experience that our clients are happy to share with their friends and colleagues. That is how our cumulative total of approved cases grew from 600 in 2013 to nearly 64,000 in 2025.

Track Record of Success EB-1 and NIW Approvals

(2012.01 - 2025.12)

Category	Approval or Refund^®		Approval or Refiling^TM
	Approval or Refund^®
Category	Approved Sum	Success Rate	Approved Sum	Success Rate
NIW	42,047	99%	5,258	97%
EB1A	9,218	91%	4,534	86%
EB1B	1,488	98%	448	93%
Total	52,753	98%	10,240	92%